B vitamins attenuate haloperidol-induced orofacial dyskinesia in rats: Possible involvement of antioxidant mechanisms

Behavioural Pharmacology

Volumn 22, Issue 7, 2011, Pages 674-680

  MacÊdo, Danielle Silveira ^a   De Oliveira, Gersilene Valente ^a   Gomes, Patrícia Xavier Lima ^a   De Araújo, Fernanda Yvelize Ramos ^a   De Souza, Carolina Melo ^a   Vasconcelos, Silvĝnia Maria Mendes ^a   De Barros Viana, Glauce Socorro ^a   De Sousa, Francisca Cléa Florenço ^a   Carvalho, André Férrer ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

haloperidol; orofacial dyskinesia; oxidative stress; rat; striatum; tardive dyskinesia

Indexed keywords

CYANOCOBALAMIN; GLUTATHIONE; HALOPERIDOL; LIPID PEROXIDE; PYRIDOXINE; THIAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; HUMAN; LIPID PEROXIDATION; MALE; NONHUMAN; OROFACIAL DYSKINESIA; OXIDATIVE STRESS; RAT;

ANIMALS; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; GLUTATHIONE; HALOPERIDOL; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MOVEMENT DISORDERS; OXIDATIVE STRESS; PSYCHOTIC DISORDERS; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; VITAMIN B COMPLEX;

EID: 80052945581     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32834aff6d     Document Type: Article

References (52)

1. Abilio VC, Araujo CC, Bergamo M, Calvente PR, D'Almeida V, Ribeiro Rde A, Frussa-Filho R (2003). Vitamin E attenuates reserpine-induced oral dyskine-sia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats. Prog Neuropsychopharmacol Biol Psychiatry 27: 109-114. (Pubitemid 36126651)
2. Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R, et al. (1999). Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry 56:836-841. (Pubitemid 29420705)
3. Bazian AS (2001). Divergent and convergent mechanisms of the integrative activity of the mammalian brain. Zh Vyssh Nerv Deiat Im I P Pavlova 51: 514-528.
4. Bishnoi M, Chopra K, Kulkarni SK (2007). Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia. Pharmacol Rep 59:181-191. (Pubitemid 46952408)
5. Bishnoi M, Chopra K, Kulkarni SK (2009). Co-administration of nitric oxide (NO) donors prevents haloperidol-induced orofacial dyskinesia, oxidative damage and change in striatal dopamine levels. Pharmacol Biochem Behav 91: 423-429.
6. Cabrini L, Bergami R, Fiorentini D, Marchetti M, Landi L, Tolomelli B (1998). Vitamin B6 deficiency affects antioxidant defences in rat liver and heart. Biochem Mol Biol Int 46:689-697. (Pubitemid 28537686)
7. Correll CU, Schenk EM (2008). Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21:151-156. (Pubitemid 351339869)
8. Costall B, Naylor RJ (1974). On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity. Psychopharmacologia 34: 233-241.
9. Dugan LL, Choi DW (1999). Hypoxic-ischemic brain injury and oxidative stress. In: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD, editors. Basic Neurochemistry: molecular, cellular and medical aspects. Philadelphia: Lippincott Williams & Wilkins. p. 723.
10. Ellenbroek B, Schwarz M, Sontag KH, Jaspers R, Cools A (1985). Muscular rigidity and delineation of a dopamine-specific neostriatal subregion: tonic EMG activity in rats. Brain Res 345:132-140. (Pubitemid 16217923)
11. Gibson GE, Zhang H (2002). Interactions of oxidative stress with thiamine homeostasis promote neurodegeneration. Neurochem Int 40:493-504. (Pubitemid 34159150)
12. Gibson GE, Sheu KF, Blass JP, Baker A, Carlson KC, Harding B, Perrino P (1988). Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol 45: 836-840.
13. Hirose G (2006). Drug induced parkinsonism: a review. J Neurol 253: III/22-III/24.
14. Hoff JI, van Hilten BJ, Roos RA (1999). A review of the assessment of dyskinesias. Mov Disord 14:737-743. (Pubitemid 29509615)
15. Hoffman DC, Donovan H (1995). Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharma-cology (Berl) 120:128-133.
16. Kane JM (2001). Extrapyramidal side effects are unacceptable. Eur Neuropsy-chopharmacol 11 (Suppl 4):S397-S403.
17. Kane JM, Woerner M, Lieberman J (1988). Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 8:52S-56S.
18. Karakula H, Opolska A, Kowal A, Domanski M, Plotka A, Perzynski J (2009). Does diet affect our mood? The significance of folic acid and homocysteine. Pol Merkur Lekarski 26:136-141.
19. Latimer PR (1995). Tardive dyskinesia: a review. Can J Psychiatry 40:S49-S54.
20. Lerner V, Kaptsan A, Miodownik C, Kotler M (1999). Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study. Clin Neuropharmacol 22:241-243. (Pubitemid 30004143)
21. Lerner V, Miodownik C, Kaptsan A, Cohen H, Matar M, Loewenthal U, Kotler M (2001). Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 158:1511-1514. (Pubitemid 32847255)
22. Lerner V, Miodownik C, Kaptsan A, Bersudsky Y, Libov I, Sela BA, Witztum E (2007). Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry 68:1648-1654. (Pubitemid 350247493)
23. Lohr JB, Kuczenski R, Niculescu AB (2003). Oxidative mechanisms and tardive dyskinesia. CNS Drugs 17:47-62. (Pubitemid 36044348)
24. Lorenc-Koci E, Wolfarth S, Ossowska K (1996). Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity. Exp Brain Res 109:268-276.
25. Mahfouz MM, Zhou SQ, Kummerow FA (2009). Vitamin B6 compounds are capable of reducing the superoxide radical and lipid peroxide levels induced by H2O2 in vascular endothelial cells in culture. Int J Vitam Nutr Res 79: 218-229.
26. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R (2005). Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1. pathophysiology and mechanisms of induction. Can J Psychiatry 50: 541-547. (Pubitemid 43161786)
27. Metz TO, Alderson NL, Thorpe SR, Baynes JW (2003). Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys 419:41-49. (Pubitemid 37272158)
28. Miodownik C, Cohen H, Kotler M, Lerner V (2003). Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah 142:592-596,647.
29. Mitchell IJ, Cooper AC, Griffiths MR, Cooper AJ (2002). Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat. Neuroscience 109:89-99. (Pubitemid 34088149)
30. Morris JK, Bomhoff GL, Stanford JA, Geiger PC (2010). Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol 299:R1082-R1090.
31. Naidu PS, Kulkarni SK (2001). Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide. Behav Pharmacol 12:209-216. (Pubitemid 32619882)
32. Naidu PS, Singh A, Kulkarni SK (2003). Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia. Neuropharmacology 44:1100-1106. (Pubitemid 36570433)
33. Nair V, Arjuman A, Gopalakrishna HN, Nandini M (2008). Effect of Withania somnifera root extract on haloperidol-induced catalepsy in albino mice. Phytother Res 22:243-246. (Pubitemid 351363245)
34. Neal-Beliveau BS, Joyce JN, Lucki I (1993). Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 265:207-217. (Pubitemid 23320963)
35. Okuyama S (1999). Atypical antipsychotic profiles of sigma receptor ligands. Nippon Yakurigaku Zasshi 114:13-23. (Pubitemid 29330384)
36. Qing H, Xu H, Wei Z, Gibson K, Li XM (2003). The ability of atypical antipsychotic drugs versus haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur J Neurosci 17:1563-1570. (Pubitemid 36628125)
37. Rasheed AS, Venkataraman S, Jayaveera KN, Fazil AM, Yasodha KJ, Aleem MA, et al. (2010). Evaluation of toxicological and antioxidant potential of Nardostachys jatamansi in reversing haloperidol-induced catalepsy in rats. Int J Gen Med 3:127-136.
38. Rogoza RM, Fairfax DF, Henry P, N-Marandi S, Khan RF, Gupta SK, Mishra RK (2004). Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert- butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia. Synapse 54:156-163. (Pubitemid 39435345)
39. Sedlak J, Hanus L (1982). Changes of glutathione and protein bound SH-groups concentration in rat adrenals under acute and repeated stress. Endocrinol Exp 16:103-109. (Pubitemid 12017099)
40. Sharma H (2009). Treatment of Tardive Dyskinesia by tetrabenazine, clonazepam and vitamin E. Indian J Psychiatry 51:162-163.
41. Sharma S, Paladino P, Gabriele J, Saeedi H, Henry P, Chang M, et al. (2003). Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: a model of human tardive dyskinesia. Peptides 24:313-319. (Pubitemid 36369353)
42. Sheu KF, Calingasan NY, Lindsay JG, Gibson GE (1998). Immunochemical characterization of the deficiency of the alpha-ketoglutarate dehydrogenase complex in thiamine-deficient rat brain. J Neurochem 70:1143-1150. (Pubitemid 28113648)
43. Sorolla MA, Rodriguez-Colman MJ, Tamarit J, Ortega Z, Lucas JJ, Ferrer I, et al. (2010). Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism. Free Radic Biol Med 49:612-621.
44. Stracke H, Lindemann A, Federlin K (1996). A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 104:311-316. (Pubitemid 26306123)
45. Stracke H, Hammes HP, Werkmann D, Mavrakis K, Bitsch I, Netzel M, et al. (2001). Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes 109:330-336. (Pubitemid 32885036)
46. Thaakur S, Himabindhu G (2009). Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats. J Neural Transm 116:807-814.
47. Trevizol F, Benvegnu DM, Barcelos RC, Pase CS, Segat HJ, Dias VT, et al. (2011). Comparative study between two animal models of extrapyramidal movement disorders: Prevention and reversion by pecan nut shell aqueous extract. Behav Brain Res 221:13-18.
48. Ukai W, Ozawa H, Tateno M, Hashimoto E, Saito T (2004). Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J Neural Transm 111:667-681. (Pubitemid 38716547)
49. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, et al. (2010). Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 71:463-474.
50. Yudkoff M, Pleasure D, Cregar L, Lin ZP, Nissim I, Stern J. Glutathione turnover in cultured astrocytes: studies with [15N]glutamate. J Neurochem 1990; 55:137-145.
51. Zai CC, Tiwari AK, Basile V, de Luca V, Muller DJ, Voineskos AN, et al. (2010). Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and superoxide dismutase 2 (SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry 34:50-56.
52. Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Haile CN, et al. (2007). Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J Clin Psychiatry 68: 754-760. (Pubitemid 46841859)